Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALB-TRIAL: Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites
2022-501006-34-01Phase 3Authorised
- Sponsor
- Odense University Hospital, European Foundation For The Study Of Chronic Liver Failure
- Start
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, randomised trial of human albumin in Cirrhosis (2 arms), sponsored by Odense University Hospital, European Foundation For The Study Of Chronic Liver Failure. Primary endpoint: Cumulative number of liver-related clinical outcomes and TIPS with death and liver transplantation as counting and censoring events. Planned start Mar 2023; status: authorised.
02
Drugs
human albumin
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on 2022-501006-34-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501006-34-01.